4 results
Primary objective:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with chronic cluster headache. The primary outcome…
Part 1:The primary objective of the study is to investigate whether treatment with natalizumab slows the accumulation of disability not related to relapses in subjects with SPMS. The secondary objectives of this study are to determine in this study…
Primary:The primary objective is to assess the efficacy of LY2951742 300 mg every 30 days compared with placebo in reducing the frequency of weekly cluster headache attacks in patients with episodic cluster headache. The primary outcome measure will…
The purpose of this study is to compare the effectiveness of treatment Arm A and Arm B by measuring the event free survival (EFS) and pathological complete response (pCR). EFS is defined as the time from the first treatment dose that the patient…